HIBISCUS : Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome
Copyright © 2018. Published by Elsevier B.V..
The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 17(2018), 12 vom: 18. Dez., Seite 1153-1168 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 11.01.2019 Date Revised 11.01.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2018.05.012 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM289518539 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM289518539 | ||
| 003 | DE-627 | ||
| 005 | 20231225062729.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2018.05.012 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0965.xml |
| 035 | |a (DE-627)NLM289518539 | ||
| 035 | |a (NLM)30316994 | ||
| 035 | |a (PII)S1568-9972(18)30229-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Belizna, Cristina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a HIBISCUS |b Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.01.2019 | ||
| 500 | |a Date Revised 11.01.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018. Published by Elsevier B.V. | ||
| 520 | |a The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Hydroxychloroquine | |
| 650 | 4 | |a Primary antiphospholipid syndrome | |
| 650 | 4 | |a Secondary prevention | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 700 | 1 | |a Pregnolato, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Abad, Sebastien |e verfasserin |4 aut | |
| 700 | 1 | |a Alijotas-Reig, Jaume |e verfasserin |4 aut | |
| 700 | 1 | |a Amital, Howard |e verfasserin |4 aut | |
| 700 | 1 | |a Amoura, Zahir |e verfasserin |4 aut | |
| 700 | 1 | |a Andreoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Andres, Emmanuel |e verfasserin |4 aut | |
| 700 | 1 | |a Aouba, Achile |e verfasserin |4 aut | |
| 700 | 1 | |a Apras Bilgen, Sule |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaud, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Bienvenu, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Bitsadze, Viktoria |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Blank, Miri |e verfasserin |4 aut | |
| 700 | 1 | |a Borghi, Maria Orietta |e verfasserin |4 aut | |
| 700 | 1 | |a Caligaro, Antonia |e verfasserin |4 aut | |
| 700 | 1 | |a Candrea, Elisabeta |e verfasserin |4 aut | |
| 700 | 1 | |a Canti, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Chiche, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Chretien, Jean Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen Tervaert, Jan Willem |e verfasserin |4 aut | |
| 700 | 1 | |a Damian, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Delross, Teresa |e verfasserin |4 aut | |
| 700 | 1 | |a Dernis, Emmanuelle |e verfasserin |4 aut | |
| 700 | 1 | |a Devreese, Katrien |e verfasserin |4 aut | |
| 700 | 1 | |a Djokovic, Aleksandra |e verfasserin |4 aut | |
| 700 | 1 | |a Esteve-Valverde, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Favaro, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Fassot, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Oliveras, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Godon, Alban |e verfasserin |4 aut | |
| 700 | 1 | |a Hamidou, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Hasan, Milena |e verfasserin |4 aut | |
| 700 | 1 | |a Henrion, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Imbert, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Jeandel, Pierre Yves |e verfasserin |4 aut | |
| 700 | 1 | |a Jeannin, Pascale |e verfasserin |4 aut | |
| 700 | 1 | |a Jego, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Jourde-Chiche, Noemie |e verfasserin |4 aut | |
| 700 | 1 | |a Khizroeva, Jamilya |e verfasserin |4 aut | |
| 700 | 1 | |a Lambotte, Olivier |e verfasserin |4 aut | |
| 700 | 1 | |a Landron, Cédric |e verfasserin |4 aut | |
| 700 | 1 | |a Latino, Jose Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Lazaro, Estibaliz |e verfasserin |4 aut | |
| 700 | 1 | |a de Leeuw, Karina |e verfasserin |4 aut | |
| 700 | 1 | |a Le Gallou, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Kiliç, Levent |e verfasserin |4 aut | |
| 700 | 1 | |a Limper, Maarten |e verfasserin |4 aut | |
| 700 | 1 | |a Loufrani, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Lubin, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Magy-Bertrand, Nadine |e verfasserin |4 aut | |
| 700 | 1 | |a Mahe, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Makatsariya, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, Thierry |e verfasserin |4 aut | |
| 700 | 1 | |a Muchardt, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Nagy, Gyorgy |e verfasserin |4 aut | |
| 700 | 1 | |a Omarjee, Loukman |e verfasserin |4 aut | |
| 700 | 1 | |a Van Paasen, Pieter |e verfasserin |4 aut | |
| 700 | 1 | |a Pernod, Gilles |e verfasserin |4 aut | |
| 700 | 1 | |a Perrinet, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Pïres Rosa, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a Pistorius, Marc Antoine |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffatti, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Fatma |e verfasserin |4 aut | |
| 700 | 1 | |a Saulnier, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Sene, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Sentilhes, Loic |e verfasserin |4 aut | |
| 700 | 1 | |a Shovman, Ova |e verfasserin |4 aut | |
| 700 | 1 | |a Sibilia, Jean |e verfasserin |4 aut | |
| 700 | 1 | |a Sinescu, Crina |e verfasserin |4 aut | |
| 700 | 1 | |a Stanisavljevic, Natasa |e verfasserin |4 aut | |
| 700 | 1 | |a Stojanovich, Ljudmila |e verfasserin |4 aut | |
| 700 | 1 | |a Tam, Lai Shan |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Tollis, Fréderic |e verfasserin |4 aut | |
| 700 | 1 | |a Udry, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Ungeheuer, Marie Noelle |e verfasserin |4 aut | |
| 700 | 1 | |a Versini, Mathilde |e verfasserin |4 aut | |
| 700 | 1 | |a Cervera, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Meroni, Pier Luigi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 17(2018), 12 vom: 18. Dez., Seite 1153-1168 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2018 |g number:12 |g day:18 |g month:12 |g pages:1153-1168 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2018.05.012 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2018 |e 12 |b 18 |c 12 |h 1153-1168 | ||